Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:TECH
- CUSIP: 87837710
- Web: www.techne-corp.com
Capitalization:- Market Cap: $4.39005 billion
- Outstanding Shares: 37,333,000
Average Prices:- 50 Day Moving Avg: $111.57
- 200 Day Moving Avg: $105.47
- 52 Week Range: $95.68 - $119.22
P/E:- Trailing P/E Ratio: 63.88
- Foreward P/E Ratio: 32.63
- P/E Growth: 3.11
Sales & Book Value:- Annual Revenue: $541.19 million
- Price / Sales: 8.19
- Book Value: $24.32 per share
- Price / Book: 4.88
Dividend:- Annual Dividend: $1.28
- Dividend Yield: 1.1%
Profitability:- EBIDTA: $201.56 million
- Net Margins: 12.86%
- Return on Equity: 13.80%
- Return on Assets: 8.65%
Debt:- Debt-to-Equity Ratio: 0.38%
- Current Ratio: 2.15%
- Quick Ratio: 1.70%
Misc:- Average Volume: 164,820 shs.
- Beta: 0.83
- Short Ratio: 10.03
Frequently Asked Questions for Bio-Techne Corp (NASDAQ:TECH)
What is Bio-Techne Corp's stock symbol?
Bio-Techne Corp trades on the NASDAQ under the ticker symbol "TECH."
How often does Bio-Techne Corp pay dividends? What is the dividend yield for Bio-Techne Corp?
Bio-Techne Corp declared a quarterly dividend on Tuesday, May 2nd. Stockholders of record on Friday, May 19th will be paid a dividend of $0.32 per share on Friday, June 2nd. This represents a $1.28 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Wednesday, May 17th. View Bio-Techne Corp's Dividend History.
How were Bio-Techne Corp's earnings last quarter?
Bio-Techne Corp (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.93 by $0.04. The business had revenue of $144.04 million for the quarter, compared to the consensus estimate of $142.83 million. Bio-Techne Corp had a net margin of 12.86% and a return on equity of 13.80%. The company's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $1.01 EPS. View Bio-Techne Corp's Earnings History.
When will Bio-Techne Corp make its next earnings announcement?
Where is Bio-Techne Corp's stock going? Where will Bio-Techne Corp's stock price be in 2017?
5 equities research analysts have issued twelve-month target prices for Bio-Techne Corp's stock. Their forecasts range from $116.00 to $125.00. On average, they expect Bio-Techne Corp's share price to reach $121.25 in the next twelve months. View Analyst Ratings for Bio-Techne Corp.
Who are some of Bio-Techne Corp's key competitors?
Some companies that are related to Bio-Techne Corp include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), PAREXEL International Corporation (PRXL), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), INC Research Holdings (INCR), Portola Pharmaceuticals (PTLA) and Nektar Therapeutics (NKTR).
Who are Bio-Techne Corp's key executives?
Bio-Techne Corp's management team includes the folowing people:
- Robert V. Baumgartner CPA, Independent Chairman of the Board
- Charles R. Kummeth, President, Chief Executive Officer, Director
- Roger C. Lucas Ph.D., Independent Vice Chairman of the Board
- James T. Hippel, Chief Financial Officer, Senior Vice President
- Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary
- David Eansor, Senior Vice President - Biotechnology
- Robert Gavin, Senior Vice President-Protein Platforms
- Kevin S. Gould, Senior Vice President-Clinical Controls
- J. Fernando Bazan Ph.D., Chief Technology Officer
- Charles A. Dinarello M.D., Independent Director
Who owns Bio-Techne Corp stock?
Bio-Techne Corp's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.38%), Vanguard Group Inc. (8.06%), Brown Capital Management LLC (5.76%), Neuberger Berman Group LLC (5.09%), State Street Corp (2.65%) and Janus Capital Management LLC (2.52%). Company insiders that own Bio-Techne Corp stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for Bio-Techne Corp.
Who sold Bio-Techne Corp stock? Who is selling Bio-Techne Corp stock?
Bio-Techne Corp's stock was sold by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, Wellington Management Group LLP, Brown Capital Management LLC, Pictet Asset Management Ltd., OppenheimerFunds Inc., Janus Capital Management LLC, Summit Creek Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Bio-Techne Corp stock in the last year include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for Bio-Techne Corp.
Who bought Bio-Techne Corp stock? Who is buying Bio-Techne Corp stock?
Bio-Techne Corp's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Neuberger Berman Group LLC, American Century Companies Inc., Vanguard Group Inc., Citadel Advisors LLC, Conestoga Capital Advisors LLC, Mackenzie Financial Corp and Bank of America Corp DE. View Insider Buying and Selling for Bio-Techne Corp.
How do I buy Bio-Techne Corp stock?
Shares of Bio-Techne Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Techne Corp's stock price today?
One share of Bio-Techne Corp stock can currently be purchased for approximately $118.76.
MarketBeat Community Rating for Bio-Techne Corp (NASDAQ TECH)MarketBeat's community ratings are surveys of what our community members think about Bio-Techne Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Bio-Techne Corp (NASDAQ:TECH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $121.25 (2.10% upside) |
Analysts' Ratings History for Bio-Techne Corp (NASDAQ:TECH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/3/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $115.00 -> $122.00 | Low |  |
| 5/3/2017 | Citigroup Inc. | Reiterated Rating | Buy | $115.00 -> $125.00 | Low | |
| 3/27/2017 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | | High | |
| 11/10/2016 | Leerink Swann | Initiated Coverage | Outperform | $122.00 | N/A | |
| 8/18/2016 | Robert W. Baird | Boost Price Target | Outperform | $115.00 -> $116.00 | N/A | |
| 11/2/2015 | Craig Hallum | Lower Price Target | Buy | $125.00 -> $110.00 | N/A | |
| 10/29/2015 | Stephens | Downgrade | Overweight -> Equal Weight | | N/A | |
(Data available from 6/29/2015 forward)
Earnings History for Bio-Techne Corp (NASDAQ:TECH)Earnings History by Quarter for Bio-Techne Corp (NASDAQ TECH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/15/2017 | | | | | | | | |
| 5/2/2017 | Q3 2017 | $0.93 | $0.97 | $142.83 million | $144.04 million | View | Listen | |
| 2/7/2017 | Q217 | $0.85 | $0.81 | $134.74 million | $131.80 million | View | Listen | |
| 10/31/2016 | Q117 | $0.79 | $0.84 | $127.47 million | $130.60 million | View | Listen | |
| 8/17/2016 | Q416 | $0.96 | $0.92 | $129.23 million | $134.80 million | View | Listen | |
| 5/3/2016 | Q316 | $0.89 | $1.01 | $122.65 million | $131.00 million | View | N/A | |
| 2/2/2016 | Q216 | $0.82 | $0.88 | $118.59 million | $120.90 million | View | N/A | |
| 10/28/2015 | Q1 | $0.85 | $0.79 | $116.91 million | $12.40 million | View | Listen | |
| 8/6/2015 | Q415 | $0.86 | $0.87 | $116.85 million | $117.70 million | View | N/A | |
| 5/5/2015 | Q315 | $0.91 | $0.86 | $119.30 million | $114.20 million | View | N/A | |
| 2/3/2015 | Q215 | $0.86 | $0.89 | $112.73 million | $111.90 million | View | N/A | |
| 10/28/2014 | Q115 | $0.87 | $0.85 | $108.65 million | $108.50 million | View | N/A | |
| 8/11/2014 | Q414 | $0.85 | $0.88 | $91.80 million | $92.50 million | View | N/A | |
| 4/28/2014 | Q314 | $0.89 | $0.94 | $92.50 million | $95.60 million | View | N/A | |
| 2/4/2014 | Q214 | $0.80 | $0.75 | $84.79 million | $84.00 million | View | N/A | |
| 10/29/2013 | Q114 | $0.80 | $0.83 | $82.36 million | $85.70 million | View | N/A | |
| 8/6/2013 | Q4 2013 | $0.83 | $0.82 | $79.71 million | $79.50 million | View | N/A | |
| 4/30/2013 | Q3 2013 | $0.90 | $0.88 | $84.00 million | $81.00 million | View | N/A | |
| 2/5/2013 | Q2 2013 | $0.77 | $0.74 | $76.40 million | $75.10 million | View | N/A | |
| 10/23/2012 | | $0.79 | $0.75 | | | View | N/A | |
| 7/31/2012 | | $0.85 | $0.80 | | | View | N/A | |
| 5/1/2012 | | $0.89 | $0.90 | | | View | N/A | |
| 1/31/2012 | | $0.79 | $0.76 | | | View | N/A | |
| 10/25/2011 | | $0.84 | $0.81 | | | View | N/A | |
| 8/2/2011 | | $0.76 | $0.76 | | | View | N/A | |
| 5/3/2011 | | $0.80 | $0.84 | | | View | N/A | |
| 2/1/2011 | | $0.68 | $0.71 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Bio-Techne Corp (NASDAQ:TECH)2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.77
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.76 | $0.81 | $0.78 |
| Q2 2017 | 3 | $0.81 | $0.85 | $0.83 |
| Q3 2017 | 3 | $0.90 | $0.96 | $0.93 |
| Q4 2017 | 3 | $0.93 | $0.98 | $0.95 |
| Q1 2018 | 1 | $0.88 | $0.88 | $0.88 |
| Q2 2018 | 1 | $0.89 | $0.89 | $0.89 |
| Q3 2018 | 1 | $0.98 | $0.98 | $0.98 |
| Q4 2018 | 1 | $1.02 | $1.02 | $1.02 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Bio-Techne Corp (NASDAQ:TECH)| Most Recent Dividend: | 6/2/2017 |
| Annual Dividend: | $1.28 |
| Dividend Yield: | 1.08% |
| Payout Ratio: | 68.82% (Trailing 12 Months of Earnings)
38.32% (Based on This Year's Estimates)
35.16% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Bio-Techne Corp (NASDAQ TECH)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/2/2017 | quarterly | $0.32 | 1.15% | 5/17/2017 | 5/19/2017 | 6/2/2017 |
| 2/7/2017 | quarterly | $0.32 | 1.27% | 2/15/2017 | 2/17/2017 | 3/3/2017 |
| 11/1/2016 | Quarterly | $0.32 | | 11/9/2016 | 11/14/2016 | 11/28/2016 |
| 8/17/2016 | quarterly | $0.32 | | 8/25/2016 | 8/29/2016 | 9/12/2016 |
| 5/3/2016 | quarterly | $0.32 | 1.27% | 5/11/2016 | 5/13/2016 | 5/27/2016 |
| 2/2/2016 | quarterly | $0.32 | 1.48% | 2/10/2016 | 2/12/2016 | 2/26/2016 |
| 10/29/2015 | quarterly | $0.32 | 1.45% | 11/10/2015 | 11/13/2015 | 11/27/2015 |
| 8/6/2015 | quarterly | $0.32 | 1.18% | 8/13/2015 | 8/17/2015 | 8/28/2015 |
| 5/5/2015 | quarterly | $0.32 | 1.31% | 5/11/2015 | 5/15/2015 | 5/29/2015 |
| 2/3/2015 | quarterly | $0.32 | 1.4% | 2/11/2015 | 2/13/2015 | 2/27/2015 |
| 10/30/2014 | quarterly | $0.32 | 1.41% | 11/6/2014 | 11/10/2014 | 11/24/2014 |
| 8/11/2014 | quarterly | $0.31 | 1.31% | 8/19/2014 | 8/21/2014 | 8/29/2014 |
| 4/28/2014 | quarterly | $0.31 | 1.37% | 5/7/2014 | 5/9/2014 | 5/23/2014 |
| 2/4/2014 | quarterly | $0.31 | 1.48% | 2/12/2014 | 2/14/2014 | 2/28/2014 |
| 10/31/2013 | quarterly | $0.31 | 1.4% | 11/7/2013 | 11/12/2013 | 11/25/2013 |
| 8/6/2013 | quarterly | $0.30 | 1.62% | 8/14/2013 | 8/16/2013 | 8/31/2013 |
| 4/30/2013 | quarterly | $0.30 | 1.86% | 5/8/2013 | 5/10/2013 | 5/24/2013 |
| 2/5/2013 | quarterly | $0.30 | 1.74% | 2/13/2013 | 2/15/2013 | 3/1/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Bio-Techne Corp (NASDAQ:TECH)Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 96.91%
Insider Trades by Quarter for Bio-Techne Corp (NASDAQ:TECH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/9/2017 | Roger C Lucas | Director | Sell | 100 | $113.62 | $11,362.00 | |
| 5/31/2017 | Charles A Dinarello | Director | Sell | 5,000 | $111.37 | $556,850.00 | |
| 5/25/2017 | Karen A Holbrook | Director | Sell | 5,000 | $111.15 | $555,750.00 | |
| 5/10/2017 | Roger C Lucas | Director | Sell | 100 | $110.59 | $11,059.00 | |
| 4/10/2017 | Roger C Lucas | Director | Sell | 100 | $101.15 | $10,115.00 | |
| 1/10/2017 | Roger C Lucas | Director | Sell | 100 | $103.57 | $10,357.00 | |
| 11/29/2016 | Karen A Holbrook | Director | Sell | 1,000 | $106.73 | $106,730.00 | |
| 11/16/2016 | Roger C Lucas | Director | Sell | 100 | $105.75 | $10,575.00 | |
| 9/21/2016 | Roger C Lucas | Director | Sell | 100 | $108.91 | $10,891.00 | |
| 9/8/2016 | John L Higgins | Director | Sell | 1,700 | $109.83 | $186,711.00 | |
| 9/8/2016 | Kevin S. Gould | SVP | Sell | 524 | $110.50 | $57,902.00 | |
| 9/2/2016 | Robert V Baumgartner | Director | Sell | 6,467 | $107.17 | $693,068.39 | |
| 8/24/2016 | Robert V Baumgartner | Director | Sell | 3,533 | $107.10 | $378,384.30 | |
| 8/17/2016 | Roger C. Lucas | Director | Sell | 100 | $113.70 | $11,370.00 | |
| 7/20/2016 | Roger C Lucas | Director | Sell | 100 | $111.03 | $11,103.00 | |
| 6/15/2016 | Roger C Lucas | Director | Sell | 100 | $112.15 | $11,215.00 | |
| 5/18/2016 | Roger C Lucas | Director | Sell | 100 | $102.53 | $10,253.00 | |
| 5/9/2016 | Charles A Dinarello | Director | Sell | 5,000 | $101.91 | $509,550.00 | |
| 5/6/2016 | Roger C Lucas | Director | Sell | 500 | $100.24 | $50,120.00 | |
| 4/20/2016 | Roger C Lucas | Director | Sell | 100 | $92.40 | $9,240.00 | |
| 3/16/2016 | Roger C Lucas | Director | Sell | 100 | $92.90 | $9,290.00 | |
| 2/5/2016 | Roger C. Lucas | Director | Sell | 5,000 | $83.68 | $418,400.00 | |
| 8/13/2015 | Roger C Lucas | Director | Sell | 5,000 | $106.01 | $530,050.00 | |
| 6/8/2015 | Randolph C Steer | Director | Sell | 1,000 | $99.39 | $99,390.00 | |
| 2/19/2015 | Howard V Oconnell | Director | Sell | 5,000 | $95.78 | $478,900.00 | |
| 12/10/2014 | Karen A Holbrook | Director | Sell | 1,000 | $92.40 | $92,400.00 | |
| 12/9/2014 | Kevin J Reagan | VP | Sell | 3,591 | $89.35 | $320,855.85 | |
| 12/8/2014 | Charles A Dinarello | Director | Sell | 3,000 | $90.44 | $271,320.00 | |
| 8/14/2014 | Karen A Holbrook | Director | Sell | 5,000 | $95.54 | $477,700.00 | |
| 5/7/2014 | Howard Oconnell | Director | Sell | 5,000 | $91.00 | $455,000.00 | |
| 3/4/2014 | Karen Holbrook | Director | Sell | 5,000 | $89.83 | $449,150.00 | |
| 2/27/2014 | Randolph Steer | Director | Sell | 5,000 | $88.78 | $443,900.00 | |
| 11/13/2013 | Randolph Steer | Director | Sell | 15,000 | $86.20 | $1,293,000.00 | |
| 11/8/2013 | Robert Baumgartner | Director | Sell | 10,000 | $87.00 | $870,000.00 | |
| 11/4/2013 | Roger C Lucas | Director | Sell | 10,000 | $87.64 | $876,400.00 | |
| 5/6/2013 | Howard V Oconnell | Director | Buy | 2,361 | $65.00 | $153,465.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Bio-Techne Corp (NASDAQ:TECH)
Latest Headlines for Bio-Techne Corp (NASDAQ:TECH)
| Source: |
|
| Date | Headline |
|---|
 | Bio-Techne Corp (TECH) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - June 27 at 4:04 PM |
| Bio-Techne Corp (TECH) Expected to Announce Quarterly Sales of $149.49 Million
www.americanbankingnews.com - June 22 at 10:10 AM |
| $0.90 EPS Expected for Bio-Techne Corp (TECH) This Quarter
www.americanbankingnews.com - June 20 at 6:44 PM |
 | ETFs with exposure to Bio-Techne Corp. : June 19, 2017
finance.yahoo.com - June 20 at 8:29 AM |
| Bio-Techne Corp. :TECH-US: Earnings Analysis: Q3, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 17 at 6:34 AM |
| FY2018 Earnings Estimate for Bio-Techne Corp (TECH) Issued By Leerink Swann
www.americanbankingnews.com - June 16 at 10:58 AM |
| Insider Selling: Bio-Techne Corp (TECH) Director Sells 100 Shares of Stock
www.americanbankingnews.com - June 13 at 9:02 PM |
| Bio-Techne Corp (TECH) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - June 13 at 7:56 PM |
| BIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 6 at 8:42 AM |
| How Washington is throwing away its shot at protecting your privacy
finance.yahoo.com - June 3 at 7:34 PM |
| BIO-TECHNE Corp (TECH) Director Charles A. Dinarello Sells 5,000 Shares
www.americanbankingnews.com - May 31 at 7:45 PM |
| Insider Selling: BIO-TECHNE Corp (TECH) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - May 30 at 7:40 PM |
| Analysts Anticipate BIO-TECHNE Corp (TECH) Will Announce Earnings of $0.90 Per Share
www.americanbankingnews.com - May 25 at 2:25 PM |
| Bio-Techne To Present At The Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 24 at 8:54 AM |
| Short Interest in BIO-TECHNE Corp (TECH) Increases By 2.1%
www.americanbankingnews.com - May 21 at 5:44 PM |
| Bio-Techne Corp. : TECH-US: Dividend Analysis : May 19th, 2017 (record date) : By the numbers : May 18, 2017
finance.yahoo.com - May 18 at 12:46 PM |
| BIO-TECHNE Corp (TECH) Director Roger C. Lucas Sells 100 Shares
www.americanbankingnews.com - May 12 at 8:48 PM |
| BIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 12 at 8:48 AM |
| Bio-Techne To Present At The Bank Of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 8 at 10:21 AM |
| BIO-TECHNE Corp (TECH) Upgraded by TheStreet to B
www.americanbankingnews.com - May 6 at 11:14 PM |
| Zacks Investment Research Upgrades BIO-TECHNE Corp (TECH) to "Hold"
www.americanbankingnews.com - May 6 at 7:34 AM |
| Blog Coverage: Sangamo Receives Special Regulatory Designation from FDA for Three of Its Program
finance.yahoo.com - May 5 at 9:06 AM |
| BIO-TECHNE Corp (TECH) Given Coverage Optimism Score of 0.18
www.americanbankingnews.com - May 4 at 5:42 PM |
| Brokerages Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $151.11 Million
www.americanbankingnews.com - May 4 at 2:04 PM |
| BIO-TECHNE Corp (TECH) Rating Reiterated by Deutsche Bank AG
www.americanbankingnews.com - May 3 at 8:48 PM |
| Investor Network: Bio-Techne to Host Earnings Call
finance.yahoo.com - May 3 at 6:23 PM |
| Citigroup Inc Reaffirms Buy Rating for BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - May 3 at 3:18 PM |
 | Bio-Techne Q3 Profit Declines, But Results Beat View - Quick Facts
www.rttnews.com - May 3 at 10:24 AM |
| Edited Transcript of TECH earnings conference call or presentation 2-May-17 1:00pm GMT
finance.yahoo.com - May 3 at 10:24 AM |
| BIO-TECHNE Corp to Issue Quarterly Dividend of $0.32 (TECH)
www.americanbankingnews.com - May 2 at 7:38 PM |
 | Bio-Techne (TECH) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 6:08 PM |
| BIO-TECHNE Corp (TECH) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 2 at 3:34 PM |
| $0.87 EPS Expected for BIO-TECHNE Corp (TECH) This Quarter
www.americanbankingnews.com - May 2 at 9:06 AM |
 | The NIH Looks Trump-Proof
www.bloomberg.com - May 2 at 9:04 AM |
 | BRIEF-Bio-Techne reports Q3 EPS $0.57
www.reuters.com - May 2 at 9:04 AM |
| Bio-Techne Releases Third Quarter Fiscal 2017 Results
finance.yahoo.com - May 2 at 9:04 AM |
| BIO-TECHNE Corp (TECH) Given Daily Coverage Optimism Score of 0.12
www.americanbankingnews.com - May 1 at 7:14 PM |
| BIO-TECHNE Corp (TECH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:20 AM |
| Bio-Techne Corp. – Value Analysis (NASDAQ:TECH) : April 27, 2017
finance.yahoo.com - April 27 at 9:05 PM |
| Favorable Media Coverage Very Unlikely to Impact BIO-TECHNE Corp (TECH) Share Price
www.americanbankingnews.com - April 27 at 4:04 PM |
| Bio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : April 26, 2017
finance.yahoo.com - April 26 at 8:53 AM |
| BIO-TECHNE Corp (TECH) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 11:45 AM |
| Bio-Techne To Present At The Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 24 at 10:30 AM |
| BIO-TECHNE Corp (TECH) Earning Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 23 at 6:58 PM |
| BIO-TECHNE Corp (TECH) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 23 at 7:38 AM |
| RNAscope Technology Reveals Replication of Zika Virus in Brains of Infants with Microcephaly and Placentas of Women with Pregnancy Losses
finance.yahoo.com - April 19 at 8:53 AM |
| Bio-Techne To Host Conference Call On May 2, 2017 To Announce Third Quarter Financial Results
finance.yahoo.com - April 18 at 8:53 AM |
| Zacks Investment Research Lowers BIO-TECHNE Corp (TECH) to Sell
www.americanbankingnews.com - April 18 at 8:36 AM |
| BIO-TECHNE Corp (TECH) Receiving Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 17 at 1:40 PM |
| BIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 9:56 AM |
Bio-Techne Corp (TECH) Chart for Thursday, June, 29, 2017
